Inclusion of POSLUMA® ((18)F-rhPSMA-7.3) PET-CT Imaging Improves Diagnostic Accuracy of Clinically-Significant Prostate Cancer Diagnosis in Men With PIRADS 2 and 3 Lesions on MRI
The goal of this study to determine if using the (18)F-rhPSMA-7.3 PET-CT scan can improve the ability to spot serious prostate cancer in patients who have uncertain MRI results. These uncertain results include MRI results that showed a PIRADS 2 or PIRADS 3 area on the prostate. The investigators want to find out if this new test is better to detect prostate cancer than just doing a biopsy based on MRI alone.
• The patient is willing to provide signed informed consent and is able to comply with all required study-related procedures, where safe and feasible.
• The patient is male and at least 18 years of age.
• The patient has not previously undergone a prostate biopsy.
• The patient underwent a pelvic mpMRI within the last 90 days for the detection of potential prostate cancer (Pca).
• The patient is a candidate for a targeted MRI/US biopsy and is scheduled to undergo the procedure. Only patients scheduled for a biopsy before recruitment will be considered candidates.
• The patient has PIRADS 2 and/or PIRADS 3 lesions detected by a board-certified radiologist.